236
Participants
Start Date
March 29, 2013
Primary Completion Date
April 23, 2019
Study Completion Date
April 23, 2019
Andecaliximab
Administered intravenous infusion
Gemcitabine
Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
Nab-paclitaxel
Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
Carboplatin
Administered intravenously on Day 1 of each 21-day treatment cycle
Pemetrexed
Administered intravenously on Day 1 of each 21-day treatment cycle
Leucovorin
Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Oxaliplatin
Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
5-FU
Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Bevacizumab
Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Irinotecan
Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
Paclitaxel
Administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle (Breast cancer) or on Day 1 of each 21-day treatment cycle (NSCLC)
Cornell University, New York
Greenville Health System, Institute for Translational Oncology Research, Greenville
Florida Cancer Specialists, Sarasota
Alabama Oncology, Birmingham
Sarah Cannon Research Institute, Nashville
Vanderbilt, Nashville
Indiana University Health Goshen Center for Cancer Care, Goshen
Parkview Research Center, Fort Wayne
Washington University School of Medicine, St Louis
UT Southwestern, Dallas
University of Utah, Salt Lake City
Pinnacle Oncology Hematology, Scottsdale
University of Southern California (USC), Los Angeles
UCLA Medical Center, Santa Monica
San Diego Pacific Oncology and Hematology Associates, Inc., Encinitas
Comprehensive Blood and Cancer Center, Bakersfield
California Pacific Medical Center, San Francisco
Northwest Medical Specialties, Tacoma
Lead Sponsor
Gilead Sciences
INDUSTRY